Brenipatide

DRUG10 trials

Sponsors

Eli Lilly & Co., Eli Lilly and Company

Conditions

Alcohol Use DisorderAsthmaBipolar DisorderDepressive Disorder, MajorObesityOpioid Use DisorderOverweightSchizophrenia

Phase 1

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Not yet recruitingNCT07476118

Eli Lilly and CompanyObesity, Overweight

Start: 2026-03-01End: 2027-02-01Target: 150Updated: 2026-03-17

Phase 2

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

RecruitingNCT07219173

Eli Lilly and CompanyAsthma

Start: 2025-10-22End: 2028-06-01Target: 531Updated: 2026-03-20

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

RecruitingNCT07223840

Eli Lilly and CompanySmoking

Start: 2025-11-03End: 2027-02-01Target: 222Updated: 2026-03-20

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

RecruitingNCT07286175

Eli Lilly and CompanyBipolar Disorder

Start: 2025-11-24End: 2027-11-01Target: 400Updated: 2026-03-20

J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma

Not yet recruitingCTIS2025-522640-41-00

Eli Lilly & Co.Asthma

Target: 73Updated: 2026-01-21

A Study of Brenipatide in Adult Participants With Schizophrenia

RecruitingNCT07410507

Eli Lilly and CompanySchizophrenia

Start: 2026-02-10End: 2027-11-01Target: 450Updated: 2026-03-25

A Study of Brenipatide in Participants With Opioid Use Disorder

RecruitingNCT07420283

Eli Lilly and CompanyOpioid Use Disorder

Start: 2026-02-13End: 2028-02-01Target: 465Updated: 2026-03-04

Phase 3

J2S-MC-GZMP: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

Not yet recruitingCTIS2025-522312-16-00

Eli Lilly & Co.Alcohol Use Disorder

Target: 67Updated: 2026-01-29

J2S-MC-GZME: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

Not yet recruitingCTIS2025-522313-38-00

Eli Lilly & Co.Alcohol Use Disorder

Target: 47Updated: 2026-02-05

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

RecruitingNCT07412756

Eli Lilly and CompanyDepressive Disorder, Major

Start: 2026-02-09End: 2028-02-01Target: 1000Updated: 2026-03-23